The field of biotechnology has grown tremendously in the last 20 years. This growth has been due to many factors, some of which include the improvements in the equipment available for bioreactors, the increased understanding of biological systems and increased knowledge as to the interactions of materials (such as monoclonal antibodies and recombinant proteins) with the various systems of the human body.
Improvements in equipment have allowed for larger volumes and lower cost for the production of biologically derived materials such as recombinant proteins. This is especially prevalent in the area of pharmaceuticals, where the successes of many types of new drug therapies have been directly due to the ability to mass produce these materials through protein-based manufacturing methods.
One of the key components that is utilized in the manufacturing processes of new biologically based pharmaceuticals is the bioreactor and the ancillary processes associated therewith. An area of growth in the bioreactor field has been with the perfusion process. The perfusion process is distinguished from the fed-batch process by its lower capital cost and higher throughput.
In the fed-batch process, a culture is seeded in a bioreactor. The gradual addition of a fresh volume of selected nutrients during the growth cycle is used to improve productivity and growth. The product is recovered after the culture is harvested. The fed batch bioreactor process has been attractive because of its simplicity and also due to carryover from well-known fermentation processes. However, a fed-batch bioreactor has high start-up costs, and generally has a large volume to obtain a cost-effective amount of product at the end of the growth cycle. After the batch is completed, the bioreactor must be cleaned and sterilized, resulting in nonproductive downtime.
A perfusion bioreactor processes a continuous supply of fresh media that is fed into the bioreactor while growth-inhibiting byproducts are constantly removed. The nonproductive downtime can be reduced or eliminated with a perfusion bioreactor process. The cell densities achieved in perfusion culture (30-100 million cells/mL) are typically higher than for fed-batch modes (5-25 million cells/mL). However, a perfusion bioreactor requires a cell retention device to prevent escape of the culture when byproducts are being removed. These cell retention systems add a level of complexity to the perfusion process, requiring management, control, and maintenance for successful operation. Operational issues such as malfunction or failure of the cell retention equipment has previously been a problem with perfusion bioreactors. This has limited their attractiveness in the past.
The present disclosure relates, in various embodiments, to a system for producing biomolecules such as recombinant proteins or monoclonal antibodies, and for separating these desirable products from a cell culture in a bioreactor. Generally, a fluid medium containing the cells and the desired products are passed or flowed through a filtering device. The present disclosure also relates, in various other embodiments, to a system for generating cells. In some embodiments, such generated cells may be for use in a cell therapy process. In such embodiments, the desired cells (e.g., T cells, B cells, or NK cells) are cultured and expanded in a host fluid in a bioreactor. The host fluid is then flowed through a filtering device to capture some of the cells, while the remaining cells continue to be cultured in the bioreactor. In some embodiments, the cells are plant cells used for bio-agriculture techniques, for example in the production of phytochemicals or insect resistant plants.
Disclosed in various embodiments is a system comprising a bioreactor and a filtering device. The bioreactor includes a reaction vessel, an agitator, a feed inlet, and an outlet. The filtering device comprises: an inlet fluidly connected to the bioreactor outlet for receiving fluid from the bioreactor; a flow chamber through which the fluid can flow; and at least one ultrasonic transducer and a reflector located opposite the at least one ultrasonic transducer, the at least one ultrasonic transducer being driven to produce a multi-dimensional standing wave in the flow chamber.
The filtering or trapping device for the bioreactor may also consist of a flow chamber with one or more ultrasonic transducers and reflectors incorporated into the flow chamber. The reflectors are set up opposite the ultrasonic transducers and the ultrasonic transducers are electronically driven to form a multi-dimensional acoustic standing wave in the flow chamber.
The flow chamber may be made from a rigid material, such as a plastic, glass or metal container. The flow chamber may alternatively be in the form of a flexible polymeric bag or pouch that is capable of being sealed and removed from the recirculation path between the bioreactor outlet through the external filtering device and a recycle inlet of the bioreactor. This flexible polymeric bag or pouch may be located between an ultrasonic transducer and a reflector such that a multi-dimensional acoustic standing wave may be generated interior to the flexible polymeric bag or pouch.
The filtering device may further comprise a product outlet through which desired product, such as expanded cells, viruses, exosomes, or phytochemicals are recovered. The filtering device can also further comprise a recycle outlet for sending fluid back to the bioreactor.
The multi-dimensional standing wave may have an axial force component and a lateral force component which are of the same order of magnitude. The bioreactor can be operated as a perfusion bioreactor.
The sleeve may be separable from the flow chamber. Sometimes, the filtering device further comprises a jacket located between the sleeve and the flow chamber, the jacket being used to regulate the temperature of the fluid in the flow chamber. The jacket, the sleeve, and the flow chamber can be separable from each other and be disposable.
In particular embodiments, the ultrasonic transducer comprises a piezoelectric material that can vibrate in a higher order mode shape. The piezoelectric material may have a rectangular shape.
The ultrasonic transducer may comprise: a housing having a top end, a bottom end, and an interior volume; and a crystal at the bottom end of the housing having an exposed exterior surface and an interior surface, the crystal being able to vibrate when driven by a voltage signal. In some embodiments, a backing layer contacts the interior surface of the crystal, the backing layer being made of a substantially acoustically transparent material. The substantially acoustically transparent material can be balsa wood, cork, or foam. The substantially acoustically transparent material may have a thickness of up to 1 inch. The substantially acoustically transparent material can be in the form of a lattice. In other embodiments, an exterior surface of the crystal is covered by a wear surface material with a thickness of a half wavelength or less, the wear surface material being a urethane, epoxy, or silicone coating. In yet other embodiments, the crystal has no backing layer or wear layer.
The ultrasonic transducer may also comprise a piezoelectric material that is polymeric such as polyvinylidene fluoride (PVDF). The PVDF may be excited at higher frequencies up to the hundreds of megahertz range such that very small particles may be trapped by the acoustic standing wave.
The multi-dimensional standing wave can be a three-dimensional standing wave.
The reflector may have a non-planar surface.
The product outlet of the filtering device may lead to a further process such as cell washing, cell concentration or cell fractionation. Such processes may be applied when the recovered product is biological cells such as T cells, B cells and NK cells. In certain embodiments, the cells used to produce viruses or exosomes are Chinese hamster ovary (CHO) cells, NSO hybridoma cells, baby hamster kidney (BHK) cells, or human cells. The use of mammalian cell cultures including the aforementioned cell types has proven to be a very efficacious way of producing/expressing the recombinant proteins and monoclonal antibodies required of today's pharmaceuticals. In some embodiments, the cells are plant cells that produce secondary metabolites and recombinant proteins and other phytochemicals.
These and other non-limiting characteristics are more particularly described below.
The following is a brief description of the drawings, which are presented for the purposes of illustrating the exemplary embodiments disclosed herein and not for the purposes of limiting the same.
The present disclosure may be understood more readily by reference to the following detailed description of desired embodiments and the examples included therein. In the following specification and the claims which follow, reference will be made to a number of terms which shall be defined to have the following meanings.
Although specific terms are used in the following description for the sake of clarity, these terms are intended to refer only to the particular structure of the embodiments selected for illustration in the drawings, and are not intended to define or limit the scope of the disclosure. In the drawings and the following description below, it is to be understood that like numeric designations refer to components of like function.
The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
The term “comprising” is used herein as requiring the presence of the named component and allowing the presence of other components. The term “comprising” should be construed to include the term “consisting of”, which allows the presence of only the named component, along with any impurities that might result from the manufacture of the named component.
Numerical values should be understood to include numerical values which are the same when reduced to the same number of significant figures and numerical values which differ from the stated value by less than the experimental error of conventional measurement technique of the type described in the present application to determine the value.
All ranges disclosed herein are inclusive of the recited endpoint and independently combinable (for example, the range of “from 2 grams to 10 grams” is inclusive of the endpoints, 2 grams and 10 grams, and all the intermediate values). The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value; they are sufficiently imprecise to include values approximating these ranges and/or values.
The modifier “about” used in connection with a quantity is inclusive of the stated value and has the meaning dictated by the context (for example, it includes at least the degree of error associated with the measurement of the particular quantity). When used in the context of a range, the modifier “about” should also be considered as disclosing the range defined by the absolute values of the two endpoints. For example, the range of “from about 2 to about 10” also discloses the range “from 2 to 10.”
It should be noted that many of the terms used herein are relative terms. For example, the terms “upper” and “lower” are relative to each other in location, i.e. an upper component is located at a higher elevation than a lower component in a given orientation, but these terms can change if the device is flipped. The terms “inlet” and “outlet” are relative to a fluid flowing through them with respect to a given structure, e.g. a fluid flows through the inlet into the structure and flows through the outlet out of the structure. The terms “upstream” and “downstream” are relative to the direction in which a fluid flows through various components, i.e. the flow fluids through an upstream component prior to flowing through the downstream component. It should be noted that in a loop, a first component can be described as being both upstream of and downstream of a second component.
The present application refers to “the same order of magnitude.” Two numbers are of the same order of magnitude if the quotient of the larger number divided by the smaller number is a value of at least 1 and less than 10.
The term “virus” refers to an infectious agent that can only replicate inside another living cell, and otherwise exists in the form of a virion formed from a capsid that surrounds and contains DNA or RNA, and in some cases a lipid envelope surrounding the capsid.
The term “exosome” refers to a vesicle, which has a lipid bilayer surrounding a core of fluid that contains proteins, DNA, and/or RNA.
The term “crystal” refers to a single crystal or polycrystalline material that is used as a piezoelectric material.
Bioreactors are useful for making biomolecules such as recombinant proteins or monoclonal antibodies. Very generally, cells are cultured in a bioreactor vessel with media in order to produce the desired product, and the desired product is then harvested by separation from the cells and media. The use of mammalian cell cultures including Chinese hamster ovary (CHO), NSO hybridoma cells, baby hamster kidney (BHK) cells, and human cells has proven to be a very efficacious way of producing/expressing the recombinant proteins and monoclonal antibodies used in pharmaceuticals. Two general types of bioreactor processes exist: fed-batch and perfusion.
While fed-batch reactors are the norm currently, due mainly to the familiarity of the process to many scientists and technicians, perfusion technology is growing at a very fast clip. Many factors favor the use of a perfusion bioreactor process. The capital and start-up costs for perfusion bioreactors are lower, smaller upstream and downstream capacity is required, and the process uses smaller volumes and fewer seed steps than fed-batch methods. A perfusion bioreactor process also lends itself better to development, scale-up, optimization, parameter sensitivity studies, and validation.
Recent developments in perfusion bioreactor technology also favor its use. Control technology and general support equipment is improving for perfusion bioreactors, increasing the robustness of perfusion processes. The perfusion process can now be scaled up to bioreactors having a volume up to 1000 liters (L). Better cell retention systems for perfusion bioreactors result in lower cell loss and greater cell densities than have been seen previously. Cell densities greater than 50 million cells/mL are now achievable, compared to fed-batch cell densities of around 20 million cells/mL. Lower contamination and infection rates have improved the output of perfusion bioreactors. Higher product concentrations in the harvest and better yields without significant increase in cost have thus resulted for perfusion processes.
A separate aspect of the use of high cell concentration bioreactors is the “dewatering” of the materials at the end of a bioreactor run. The “dewatering” or removal of interstitial fluid from a bioreactor sludge is important for improving the efficiency of recovery of the intended bioreactor product. Currently, high energy centrifuges with internal structures (known as disk stack centrifuges) are utilized to remove the interstitial fluid from the bioreactor sludge at the end of a run. The capital cost and operating costs for a disk stack centrifuge is high. A simpler method of removing the interstitial fluid from the remaining bioreactor sludge that can be performed without the high capital and operating costs associated with disk stack centrifuges is desirable. In addition, current methods of filtration or centrifugation can damage cells, releasing protein debris and enzymes into the purification process and increasing the load on downstream portions of the purification system.
Briefly, the present disclosure relates to the generation of multi-dimensional (e.g., three-dimensional (3-D)) acoustic standing wave(s) from one or more piezoelectric transducers, where the transducers are electrically or mechanically excited such that they move in a “drumhead” or multi-excitation mode (i.e., multi-mode displacement pattern), rather than a “piston” or single excitation mode fashion. Through this manner of acoustic standing wave generation, a higher lateral trapping force is generated than if the piezoelectric transducer is excited in a “piston” mode where only one large standing wave is generated. Thus, with the same input power to a piezoelectric transducer, the multi-dimensional (e.g., 3-D) acoustic standing wave(s) can have a higher lateral trapping force compared to a single planar acoustic standing wave. The input power is tunable for a controlled flow. This can be used to facilitate proteinaceous fluid purification of the contents of a bioreactor. Thus, the present disclosure relates to processing systems comprising a bioreactor and a filtering device, the filtering device using acoustophoresis for separation of various components.
Through utilization of an acoustophoretic filtering device that incorporates a multi-dimensional (e.g., 3-D) standing wave, maintaining flux rates and minimizing cross-contamination risk in a multiproduct system can also be achieved. Other benefits, such as cleaning procedures and related demands often detailed and validated within standard operating procedures (SOP), can also be realized through the use of a multi-dimensional (e.g., 3-D) acoustic standing wave capable apparatus. The cross-contamination risk can be eliminated between the bioreactor and outside processes.
Acoustophoresis is a low-power, no-pressure-drop, no-clog, solid-state approach to particle removal from fluid dispersions: i.e., it is used to achieve separations that are more typically performed with porous filters, but it has none of the disadvantages of filters. In particular, the present disclosure provides filtering devices that are suitable for use with bioreactors and operate at the macro-scale for separations in flowing systems with high flow rates. The acoustophoretic filtering device is designed to create a high intensity multi-dimensional (e.g., three dimensional) ultrasonic standing wave that results in an acoustic radiation force that is larger than and can overcome the combined effects of fluid drag and buoyancy or gravity at certain flow rates, and is therefore able to trap (i.e., hold stationary) the suspended phase (i.e. cells) to allow more time for the acoustic wave to increase particle concentration, agglomeration and/or coalescence. Put another way, the radiation force of the acoustic standing wave(s) acts as a filter that prevents or retards targeted particles (e.g., biological cells) from crossing through the standing wave(s). The present systems have the ability to create ultrasonic standing wave fields that can trap particles in flow fields with a linear velocity ranging from 0.1 mm/sec to velocities exceeding 1 cm/s. As explained above, the trapping capability of a standing wave may be varied as desired, for example by varying the flow rate of the fluid, the acoustic radiation force, and the shape of the acoustic filtering device to maximize cell retention through trapping and settling. This technology offers a green and sustainable alternative for separation of secondary phases with a significant reduction in cost of energy. Excellent particle separation efficiencies have been demonstrated for particle sizes as small as one micron.
The ultrasonic standing waves can be used to trap, i.e., hold stationary, secondary phase particles (e.g. cells) in a host fluid stream (e.g. cell culture media). This is an important distinction from previous approaches where particle trajectories were merely altered by the effect of the acoustic radiation force. The scattering of the acoustic field off the particles results in a three dimensional acoustic radiation force, which acts as a three-dimensional trapping field. The acoustic radiation force is proportional to the particle volume (e.g. the cube of the radius) when the particle is small relative to the wavelength. It is proportional to frequency and the acoustic contrast factor. It also scales with acoustic energy (e.g. the square of the acoustic pressure amplitude). For harmonic excitation, the sinusoidal spatial variation of the force is what drives the particles to the stable positions within the standing waves. When the acoustic radiation force exerted on the particles is stronger than the combined effect of fluid drag force and buoyancy/gravitational force, the particle is trapped within the acoustic standing wave field. The action of the acoustic forces (i.e., the lateral and axial acoustic forces) on the trapped particles results in formation of tightly-packed clusters through concentration, clustering, clumping, agglomeration and/or coalescence of particles that, when reaching a critical size, settle continuously through enhanced gravity for particles heavier than the host fluid or rise out through enhanced buoyancy for particles lighter than the host fluid. Additionally, secondary inter-particle forces, such as Bjerkness forces, aid in particle agglomeration.
Generally, the 3-D standing wave(s) filtering system is operated at a voltage such that the protein-producing materials, such as Chinese hamster ovary cells (CHO cells), the most common host for the industrial production of recombinant protein therapeutics, are trapped in the ultrasonic standing wave, i.e., remain in a stationary position. Within each nodal plane, the CHO cells are trapped in the minima of the acoustic radiation potential. Most biological cell types present a higher density and lower compressibility than the medium in which they are suspended, so that the acoustic contrast factor between the cells and the medium has a positive value. As a result, the axial acoustic radiation force (ARF) drives the biological cells towards the standing wave pressure nodes. The axial component of the acoustic radiation force drives the cells, with a positive contrast factor, to the pressure nodal planes, whereas cells or other particles with a negative contrast factor are driven to the pressure anti-nodal planes. The radial or lateral component of the acoustic radiation force is the force that traps the cells. The radial or lateral component of the ARF is larger than the combined effect of fluid drag force and gravitational force. For small cells or emulsions the drag force FD can be expressed as:
where Uf and Up are the fluid and cell velocity, Rp is the particle radius, μf and μp are the dynamic viscosity of the fluid and the cells, and {circumflex over (μ)}=μp/μf is the ratio of dynamic viscosities. The buoyancy force FB is expressed as:
To determine when a cell is trapped in the ultrasonic standing wave, the force balance on the cell may be assumed to be zero, and therefore an expression for lateral acoustic radiation force FLRF can be found, which is given by:
FLRF=FD+FB.
For a cell of known size and material property, and for a given flow rate, this equation can be used to estimate the magnitude of the lateral acoustic radiation force.
One theoretical model that is used to calculate the acoustic radiation force is based on the formulation developed by Gor'kov. The primary acoustic radiation force FA is defined as a function of a field potential U, FA=−Δ(U),
where the field potential U is defined as
and f1 and f2 are the monopole and dipole contributions defined by
where p is the acoustic pressure, u is the fluid particle velocity, Λ is the ratio of cell density ρp to fluid density ρf, σ is the ratio of cell sound speed cp to fluid sound speed cf, V0 is the volume of the cell, and < > indicates time averaging over the period of the wave.
Gor'kov's theory is limited to particle sizes that are small with respect to the wavelength of the sound fields in the fluid and the particle, and it also does not take into account the effect of viscosity of the fluid and the particle on the radiation force. Additional theoretical and numerical models have been developed for the calculation of the acoustic radiation force for a particle without any restriction as to particle size relative to wavelength. These models also include the effect of fluid and particle viscosity, and therefore are a more accurate calculation of the acoustic radiation force. The models that were implemented are based on the theoretical work of Yurii Ilinskii and Evgenia Zabolotskaya as described in AIP Conference Proceedings, Vol. 1474-1, pp. 255-258 (2012). Additional in-house models have been developed to calculate acoustic trapping forces for cylindrical shaped objects, such as the “hockey pucks” of trapped particles in the standing wave, which closely resemble a cylinder.
The lateral force component of the total acoustic radiation force (ARF) generated by the ultrasonic transducer(s) of the present disclosure is significant and is sufficient to overcome the fluid drag force at linear velocities of up to 1 cm/s, and to create tightly packed clusters, and is of the same order of magnitude as the axial force component of the total acoustic radiation force. This lateral ARF can thus be used to retain cells in a bioreactor while the bioreactor process continues. This is especially true for a perfusion bioreactor.
The filtering devices of the present disclosure, which use ultrasonic transducers and acoustophoresis, can also improve the dewatering of the leftover material from a bioreactor batch (i.e. bioreactor sludge), and thus reduce the use of or eliminate the use of disk stack centrifuges. This use or application of ultrasonic transducers and acoustophoresis simplifies processing and reduces costs.
In a perfusion bioreactor system, it is desirable to be able to filter and separate the cells and cell debris from the expressed materials that are in the fluid stream (i.e. cell culture media). The expressed materials are composed of biomolecules such as recombinant proteins or monoclonal antibodies, and are the desired product to be recovered.
An acoustophoretic filtering device can be used in at least two different ways. First, the standing waves can be used to trap the expressed biomolecules and separate this desired product from the cells, cell debris, and media. The expressed biomolecules can then be diverted and collected for further processing. Alternatively, the standing waves can be used to trap the cells and cell debris present in the cell culture media. The cells and cell debris, having a positive contrast factor, move to the nodes (as opposed to the anti-nodes) of the standing wave. As the cells and cell debris agglomerate at the nodes of the standing wave, there is also a physical scrubbing of the cell culture media that occurs whereby more cells are trapped as they come in contact with the cells that are already held within the standing wave. This generally separates the cells and cellular debris from the cell culture media. When the cells in the standing wave agglomerate to the extent where the mass is no longer able to be held by the acoustic wave, the aggregated cells and cellular debris that have been trapped can fall out of the fluid stream through gravity, and can be collected separately. To aid this gravitational settling of the cells and cell debris, the standing wave may be interrupted to allow all of the cells to fall out of the fluid stream that is being filtered. This process can be useful for dewatering. The expressed biomolecules may have been removed beforehand, or remain in the fluid stream (i.e. cell culture medium).
Desirably, the ultrasonic transducer(s) generate a multi-dimensional (e.g., three-dimensional) standing wave in the fluid that exerts a lateral force on the suspended particles to accompany the axial force so as to increase the particle trapping capabilities of the acoustophoretic filtering device. Typical results published in literature state that the lateral force is two orders of magnitude smaller than the axial force. In contrast, the technology disclosed in this application provides for a lateral force to be of the same order of magnitude as the axial force.
In the present disclosure, a perfusion bioreactor can also be used to generate cells that can subsequently be used for cell therapy. In this type of process, the biological cells to be used in the cell therapy are cultured in the bioreactor and expanded (i.e. to increase the number of cells in the bioreactor through cell reproduction). These cells may be lymphocytes such as T cells (e.g., regulatory T-cells (Tregs), Jurkat T-cells), B cells, or NK cells; their precursors, such as peripheral blood mononuclear cells (PBMCs); and the like. The cell culture media (a.k.a. host fluid), containing some cells, is then sent to a filtering device that produces an acoustic standing wave. A portion of the cells are trapped and held in the acoustic standing wave, while the remaining host fluid and other cells in the host fluid are returned to the bioreactor. As the quantity of trapped cells increases, they form larger clusters that will fall out of the acoustic standing wave at a critical size due to gravity forces. The clusters can fall into a product outlet outside a region of the acoustic standing wave, such as below the acoustic standing wave, from which the cells can be recovered for use in cell therapy. Only a small portion of the cells are trapped and removed from the bioreactor via the product outlet, and the remainder continue to reproduce in the bioreactor, allowing for continuous production and recovery of the desired cells.
In another application, acoustic standing waves are used to trap and hold biological cells and to separate viruses (e.g. lentiviruses) or exosomes that are produced by the biological cells. In these embodiments, the biological cells are returned to the bioreactor post-separation to continue production of viruses or exosomes.
In these applications, the acoustic filtering devices of the present disclosure can act as a cell retention device. The acoustic cell retention systems described herein operate over a range of cell recirculation rates, efficiently retain cells over a range of perfusion (or media removal) rates, and can be tuned to fully retain or selectively pass some percentage of cells through fluid flow rate, transducer power or frequency manipulation. Power and flow rates can all be monitored and used as feedback in an automated control system.
The cells of interest may also be held in the flow chamber of the external filtering device through the use of an acoustic standing wave such that other moieties may be introduced in close proximity to and for the purpose of changing the target cells. Such an operation would include the trapping of T cells and the subsequent introduction of modified lentivirus materials with a specific gene splice such that the lentivirus with a specific gene splice will transfect the T cell and generate a chimeric antigen receptor T cell also known as a CAR-T cell.
The acoustic filtering devices of the present disclosure are designed to maintain a high intensity three-dimensional acoustic standing wave. The device is driven by a function generator and amplifier (not shown). The device performance is monitored and controlled by a computer. It may be desirable, at times, due to acoustic streaming, to modulate the frequency or voltage amplitude of the standing wave. This modulation may be done by amplitude modulation and/or by frequency modulation. The duty cycle of the propagation of the standing wave may also be utilized to achieve certain results for trapping of materials. In other words, the acoustic beam may be turned on and shut off at different frequencies to achieve desired results.
Turning now to the perfusion bioreactor 202 on the right-hand side, again, the bioreactor includes a reaction vessel 220 with a feed inlet 222 for the cell culture media. An agitator 225 is used to circulate the media throughout the cell culture. An outlet 224 of the reaction vessel is fluidly connected to the inlet 232 of a filtering device 230, and continuously feeds the media (containing cells and desired product) to the filtering device. The filtering device 230 is located downstream of the reaction vessel, and separates the desired product from the cells. The filtering device 230 has two separate outlets, a product outlet 234 and a recycle outlet 236. The product outlet 234 fluidly connects the filtering device 230 to a containment vessel 240 downstream of the filtering device, which receives a concentrated flow of the desired product (plus media) from the filtering device. From there, further processing/purification can occur to isolate/recover the desired product. The recycle outlet 236 fluidly connects the filtering device 230 back to a recycle inlet 226 of the reaction vessel 220, and is used to send the cells and cell culture media back into the reaction vessel for continued growth/production. Put another way, there is a fluid loop between the reaction vessel and the filtering device. The reaction vessel 220 in the perfusion bioreactor system 202 has a continuous throughput of product and thus can be made smaller than the fed-batch bioreactor system 201. The filtering process is critical to the throughput of the perfusion bioreactor. A poor filtering process will allow for only low throughput and result in low yields of the desired product.
The perfusion systems of the present disclosure also use an acoustophoretic filtering device. The contents of the bioreactor are continuously flowed through the filtering device to capture the desired products.
In additional embodiments, it is particularly contemplated that the filtering device 630 is in the form of a flexible bag or pouch. Such a filtering device is illustrated in
Referring to both
In other embodiments, it is particularly contemplated that a flexible bag or pouch is used within the flow chamber of the filtering device 630 for the capture of cells. This flexible bag or pouch is similar to the bag 700 of
Within the flexible bag, as the quantity of trapped cells increases, the cells form larger clusters that will fall out of the acoustic standing wave at a critical size due to gravity forces. The clusters fall to the bottom of the bag. Eventually, as the bag fills up with concentrated cells, the fluid flow through the filtering device 630 is stopped. The bag filled with concentrated cells can then be removed and a new bag placed within the filtering device 630. Referring to
It may be helpful now to describe the ultrasonic transducer(s) used in the acoustophoretic filtering device in more detail.
Screws (not shown) attach an aluminum top plate 82a of the housing to the body 82b of the housing via threads 88. The top plate includes a connector 84 to pass power to the PZT crystal 86. The bottom and top surfaces of the PZT crystal 86 are each connected to an electrode (positive and negative), such as silver or nickel. A wrap-around electrode tab 90 connects to the bottom electrode and is isolated from the top electrode. Electrical power is provided to the PZT crystal 86 through the electrodes on the crystal, with the wrap-around tab 90 being the ground connection point. Note that the crystal 86 has no backing layer or epoxy layer as is present in
The transducer design can affect performance of the system. A typical transducer is a layered structure with the ceramic crystal bonded to a backing layer and a wear plate. Because the transducer is loaded with the high mechanical impedance presented by the standing wave, the traditional design guidelines for wear plates, e.g., half wavelength thickness for standing wave applications or quarter wavelength thickness for radiation applications, and manufacturing methods may not be appropriate. Rather, in one embodiment of the present disclosure the transducers, there is no wear plate or backing, allowing the crystal to vibrate in one of its eigenmodes with a high Q-factor. The vibrating ceramic crystal/disk is directly exposed to the fluid flowing through the flow chamber.
Removing the backing (e.g. making the crystal air backed) also permits the ceramic crystal to vibrate at higher order modes of vibration with little damping (e.g. higher order modal displacement). In a transducer having a crystal with a backing, the crystal vibrates with a more uniform displacement, like a piston. Removing the backing allows the crystal to vibrate in a non-uniform displacement mode. The higher order the mode shape of the crystal, the more nodal lines the crystal has. The higher order modal displacement of the crystal creates more trapping lines, although the correlation of trapping line to node is not necessarily one to one, and driving the crystal at a higher frequency will not necessarily produce more trapping lines.
In some embodiments, the crystal may have a backing that minimally affects the Q-factor of the crystal (e.g. less than 5%). The backing may be made of a substantially acoustically transparent material such as balsa wood, foam, or cork which allows the crystal to vibrate in a higher order mode shape and maintains a high Q-factor while still providing some mechanical support for the crystal. The backing layer may be a solid, or may be a lattice having holes through the layer, such that the lattice follows the nodes of the vibrating crystal in a particular higher order vibration mode, providing support at node locations while allowing the rest of the crystal to vibrate freely. The goal of the lattice work or acoustically transparent material is to provide support without lowering the Q-factor of the crystal or interfering with the excitation of a particular mode shape.
Placing the crystal in direct contact with the fluid also contributes to the high Q-factor by avoiding the dampening and energy absorption effects of the epoxy layer and the wear plate. Other embodiments may have wear plates or a wear surface to prevent the PZT, which contains lead, contacting the host fluid. This may be desirable in, for example, biological applications such as separating blood. Such applications might use a wear layer such as chrome, electrolytic nickel, or electroless nickel. Chemical vapor deposition could also be used to apply a layer of poly(p-xylylene) (e.g. Parylene) or other polymer. Organic and biocompatible coatings such as silicone or polyurethane are also usable as a wear surface.
In some embodiments, the ultrasonic transducer has a 1 inch diameter and a nominal 2 MHz resonance frequency. Each transducer can consume about 28 W of power for droplet trapping at a flow rate of 3 GPM. This power usage translates to an energy cost of 0.25 kW hr/m3. This measure is an indication of the very low cost of energy of this technology. Desirably, each transducer is powered and controlled by its own amplifier. In other embodiments, the ultrasonic transducer uses a square crystal, for example with 1″×1″ dimensions. Alternatively, the ultrasonic transducer can use a rectangular crystal, for example with 1″×2.5″ dimensions. Power dissipation per transducer was 10 W per 1″×1″ transducer cross-sectional area and per inch of acoustic standing wave span in order to get sufficient acoustic trapping forces. For a 4″ span of an intermediate scale system, each 1″×1″ square transducer consumes 40 W. The larger 1″×2.5″ rectangular transducer uses 100 W in an intermediate scale system. The array of three 1″×1″ square transducers would consume a total of 120 W and the array of two 1″×2.5″ transducers would consume about 200 W. Arrays of closely spaced transducers represent alternate potential embodiments of the technology. Transducer size, shape, number, and location can be varied as desired to generate desired three-dimensional acoustic standing wave patterns.
The size, shape, and thickness of the transducer determine the transducer displacement at different frequencies of excitation, which in turn affects separation efficiency. Typically, the transducer is operated at frequencies near the thickness resonance frequency (half wavelength). Gradients in transducer displacement typically result in more trapping locations for the cells/biomolecules. Higher order modal displacements generate three-dimensional acoustic standing waves with strong gradients in the acoustic field in all directions, thereby creating equally strong acoustic radiation forces in all directions, leading to multiple trapping lines, where the number of trapping lines correlate with the particular mode shape of the transducer.
To investigate the effect of the transducer displacement profile on acoustic trapping force and separation efficiencies, an experiment was repeated ten times using a 1″×1″ square transducer, with all conditions identical except for the excitation frequency. Ten consecutive acoustic resonance frequencies, indicated by circled numbers 1-9 and letter A on
As the oil-water emulsion passed by the transducer, the trapping lines of oil droplets were observed and characterized. The characterization involved the observation and pattern of the number of trapping lines across the fluid channel, as shown in
In the present system examples, the system is operated at a voltage such that the particles (i.e. biomolecules or cells) are trapped in the ultrasonic standing wave, i.e., remain in a stationary position. The particles are collected in along well defined trapping lines, separated by half a wavelength. Within each nodal plane, the particles are trapped in the minima of the acoustic radiation potential. The axial component of the acoustic radiation force drives particles with a positive contrast factor to the pressure nodal planes, whereas particles with a negative contrast factor are driven to the pressure anti-nodal planes. The radial or lateral component of the acoustic radiation force is the force that traps the particle. It therefore, for particle trapping, is larger than the combined effect of fluid drag force and gravitational force. In systems using typical transducers, the radial or lateral component of the acoustic radiation force is typically several orders of magnitude smaller than the axial component of the acoustic radiation force. However, the lateral force generated by the transducers of the present disclosure can be significant, on the same order of magnitude as the axial force component, and is sufficient to overcome the fluid drag force at linear velocities of up to 1 cm/s.
The lateral force can be increased by driving the transducer in higher order mode shapes, as opposed to a form of vibration where the crystal effectively moves as a piston having a uniform displacement. The acoustic pressure is proportional to the driving voltage of the transducer. The electrical power is proportional to the square of the voltage. The transducer is typically a thin piezoelectric plate, with electric field in the z-axis and primary displacement in the z-axis. The transducer is typically coupled on one side by air (i.e. the air gap within the transducer) and on the other side by the fluid of the cell culture media. The types of waves generated in the plate are known as composite waves. A subset of composite waves in the piezoelectric plate is similar to leaky symmetric (also referred to as compressional or extensional) Lamb waves. The piezoelectric nature of the plate typically results in the excitation of symmetric Lamb waves. The waves are leaky because they radiate into the water layer, which result in the generation of the acoustic standing waves in the water layer. Lamb waves exist in thin plates of infinite extent with stress free conditions on its surfaces. Because the transducers of this embodiment are finite in nature, the actual modal displacements are more complicated.
The transducers are driven so that the piezoelectric crystal vibrates in higher order modes of the general formula (m, n), where m and n are independently 1 or greater. Generally, the transducers will vibrate in higher order modes than (2,2). Higher order modes will produce more nodes and antinodes, result in three-dimensional standing waves in the fluid layer, characterized by strong gradients in the acoustic field in all directions, not only in the direction of the standing waves, but also in the lateral directions. As a consequence, the acoustic gradients result in stronger trapping forces in the lateral direction.
In embodiments, the pulsed voltage signal driving the transducer can have a sinusoidal, square, sawtooth, or triangle waveform; and have a frequency of 500 kHz to 10 MHz. The pulsed voltage signal can be driven with pulse width modulation, which produces any desired waveform. The pulsed voltage signal can also have amplitude or frequency modulation start/stop capability to eliminate streaming.
The transducer(s) is/are used to create a pressure field that generates forces of the same order of magnitude both orthogonal to the standing wave direction and in the standing wave direction. When the forces are roughly the same order of magnitude, particles of size 0.1 microns to 300 microns will be moved more effectively towards regions of agglomeration (“trapping lines”). Because of the equally large gradients in the orthogonal acoustophoretic force component, there are “hot spots” or particle collection regions that are not located in the regular locations in the standing wave direction between the transducer and the reflector. Hot spots are located in the maxima or minima of acoustic radiation potential. Such hot spots represent particle collection locations which allow for better wave transmission between the transducer and the reflector during collection and stronger inter-particle forces, leading to faster and better particle agglomeration.
Referring to
Acoustophoretic separation has been tested on different lines of Chinese hamster ovary (CHO) cells. In one experiment, a solution with a starting cell density of 8.09×106 cells/mL, a turbidity of 1.232 NTU, and cell viability of roughly 75% was separated using a system as depicted in
In another experiment, a solution with a starting cell density of 8.09×106 cells/mL, a turbidity of 1.232 NTU, and cell viability of roughly 75% was separated. This CHO cell line had a bi-modal particle size distribution (at size 12 μm and 20 μm). The result is shown in
In other tests at a flow rate of 10 L/hr, 99% of cells were captured with a confirmed cell viability of more than 99%. Other tests at a flow rate of 50 mL/min (i.e. 3 L/hr) obtained a final cell density of 3×106 cells/mL with a viability of nearly 100% and little to no temperature rise. In yet other tests, a 95% reduction in turbidity was obtained at a flow rate of 6 L/hr.
Further testing was performed using yeast as a simulant for CHO for the biological applications. For these tests, at a flow rate of 15 L/hr, various frequencies were tested as well as power levels. Table 1 shows the results of the testing.
In biological applications, it is contemplated that all of the parts of the system (e.g. the flow chamber, tubing leading to and from the bioreactor or filtering device, the sleeve containing the ultrasonic transducer and the reflector, the temperature-regulating jacket, etc.) can be separated from each other and be disposable. Avoiding centrifuges and filters allows better separation of the CHO cells without lowering the viability of the cells. The transducers may also be driven to create rapid pressure changes to prevent or clear blockages due to agglomeration of CHO cells. The frequency of the transducers may also be varied to obtain optimal effectiveness for a given power.
The present disclosure has been described with reference to exemplary embodiments. Modifications and alterations will occur to others upon reading and understanding the preceding detailed description. It is intended that the present disclosure be construed as including all such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
This application is a continuation of U.S. patent application Ser. No. 15/238,624, filed Aug. 16, 2016, which is a continuation-in-part of U.S. patent application Ser. No. 14/175,766, filed Feb. 7, 2014, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/761,717, filed on Feb. 7, 2013, and which is also a continuation-in-part of U.S. patent application Ser. No. 14/026,413, filed on Sep. 13, 2013, which is also a continuation-in-part of U.S. Ser. No. 13/844,754, filed Mar. 15, 2013, which claimed the benefit of U.S. Provisional Patent Application Ser. No. 61/708,641, filed on Oct. 2, 2012, and of U.S. Provisional Patent Application Ser. No. 61/611,159, filed Mar. 15, 2012, and of U.S. Provisional Patent Application Ser. No. 61/611,240, also filed Mar. 15, 2012, and of U.S. Provisional Patent Application Ser. No. 61/754,792, filed Jan. 21, 2013. These applications are incorporated herein by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
2473971 | Ross | Jun 1949 | A |
2667944 | Crites | Feb 1954 | A |
3372370 | Cyr | Mar 1968 | A |
3555311 | Weber | Jan 1971 | A |
4055491 | Porath-Furedi | Oct 1977 | A |
4065875 | Srna | Jan 1978 | A |
4118649 | Schwartzman et al. | Oct 1978 | A |
4158629 | Sawyer | Jun 1979 | A |
4165273 | Azarov et al. | Aug 1979 | A |
4173725 | Asai et al. | Nov 1979 | A |
4204096 | Barcus et al. | May 1980 | A |
4254661 | Kossoff et al. | Mar 1981 | A |
4320659 | Lynnworth et al. | Mar 1982 | A |
4344448 | Potts | Aug 1982 | A |
4398325 | Piaget et al. | Aug 1983 | A |
4552669 | Sekellick | Nov 1985 | A |
4666595 | Graham | May 1987 | A |
4673512 | Schram | Jun 1987 | A |
4699588 | Zinn et al. | Oct 1987 | A |
4743361 | Schram | May 1988 | A |
4759775 | Peterson et al. | Jul 1988 | A |
4800316 | Ju-Zhen | Jan 1989 | A |
4821838 | Chen | Apr 1989 | A |
4836684 | Javorik et al. | Jun 1989 | A |
4860993 | Goode | Aug 1989 | A |
4878210 | Mitome | Oct 1989 | A |
4983189 | Peterson et al. | Jan 1991 | A |
5059811 | King et al. | Oct 1991 | A |
5062965 | Bernou et al. | Nov 1991 | A |
5085783 | Feke et al. | Feb 1992 | A |
5164094 | Stuckart | Nov 1992 | A |
5225089 | Benes et al. | Jul 1993 | A |
5371429 | Manna | Dec 1994 | A |
5395592 | Bolleman et al. | Mar 1995 | A |
5431817 | Braatz et al. | Jul 1995 | A |
5443985 | Lu et al. | Aug 1995 | A |
5452267 | Spevak | Sep 1995 | A |
5475486 | Paoli | Dec 1995 | A |
5484537 | Whitworth | Jan 1996 | A |
5527460 | Trampler et al. | Jun 1996 | A |
5560362 | Sliwa, Jr. et al. | Oct 1996 | A |
5594165 | Madanshetty | Jan 1997 | A |
5604301 | Mountford et al. | Feb 1997 | A |
5626767 | Trampler et al. | May 1997 | A |
5688405 | Dickinson et al. | Nov 1997 | A |
5711888 | Trampler et al. | Jan 1998 | A |
5831166 | Kozuka et al. | Nov 1998 | A |
5834871 | Puskas | Nov 1998 | A |
5902489 | Yasuda et al. | May 1999 | A |
5912182 | Coakley et al. | Jun 1999 | A |
5947299 | Vazquez et al. | Sep 1999 | A |
5951456 | Scott | Sep 1999 | A |
6090295 | Raghavarao et al. | Jul 2000 | A |
6166231 | Hoeksema | Dec 2000 | A |
6205848 | Faber et al. | Mar 2001 | B1 |
6216538 | Yasuda et al. | Apr 2001 | B1 |
6273262 | Yasuda et al. | Aug 2001 | B1 |
6332541 | Coakley et al. | Dec 2001 | B1 |
6391653 | Letcher et al. | May 2002 | B1 |
6475151 | Koger et al. | Nov 2002 | B2 |
6482327 | Mori et al. | Nov 2002 | B1 |
6487095 | Malik et al. | Nov 2002 | B1 |
6592821 | Wada et al. | Jul 2003 | B1 |
6641708 | Becker et al. | Nov 2003 | B1 |
6649069 | DeAngelis | Nov 2003 | B2 |
6699711 | Hahn et al. | Mar 2004 | B1 |
6727451 | Fuhr et al. | Apr 2004 | B1 |
6763722 | Fjield et al. | Jul 2004 | B2 |
6881314 | Wang et al. | Apr 2005 | B1 |
6929750 | Laurell et al. | Aug 2005 | B2 |
6936151 | Lock et al. | Aug 2005 | B1 |
7008540 | Weavers et al. | Mar 2006 | B1 |
7010979 | Scott | Mar 2006 | B2 |
7061163 | Nagahara et al. | Jun 2006 | B2 |
7081192 | Wang et al. | Jul 2006 | B1 |
7093482 | Berndt | Aug 2006 | B2 |
7108137 | Lal et al. | Sep 2006 | B2 |
7150779 | Meegan, Jr. | Dec 2006 | B2 |
7186502 | Vesey | Mar 2007 | B2 |
7191787 | Redeker et al. | Mar 2007 | B1 |
7322431 | Ratcliff | Jan 2008 | B2 |
7331233 | Scott | Feb 2008 | B2 |
7340957 | Kaduchak et al. | Mar 2008 | B2 |
7373805 | Hawkes et al. | May 2008 | B2 |
7541166 | Belgrader et al. | Jun 2009 | B2 |
7601267 | Haake et al. | Oct 2009 | B2 |
7673516 | Janssen et al. | Mar 2010 | B2 |
7837040 | Ward et al. | Nov 2010 | B2 |
7846382 | Strand et al. | Dec 2010 | B2 |
7968049 | Takahashi et al. | Jun 2011 | B2 |
8075786 | Bagajewicz | Dec 2011 | B2 |
8080202 | Takahashi et al. | Dec 2011 | B2 |
8134705 | Kaduchak et al. | Mar 2012 | B2 |
8256076 | Feller | Sep 2012 | B1 |
8266950 | Kaduchak et al. | Sep 2012 | B2 |
8273253 | Curran | Sep 2012 | B2 |
8273302 | Takahashi et al. | Sep 2012 | B2 |
8309408 | Ward et al. | Nov 2012 | B2 |
8319398 | Vivek et al. | Nov 2012 | B2 |
8334133 | Fedorov et al. | Dec 2012 | B2 |
8387803 | Thorslund et al. | Mar 2013 | B2 |
8592204 | Lipkens et al. | Nov 2013 | B2 |
8679338 | Rietman et al. | Mar 2014 | B2 |
8691145 | Dionne et al. | Apr 2014 | B2 |
8873051 | Kaduchak et al. | Oct 2014 | B2 |
8889388 | Wang et al. | Nov 2014 | B2 |
9272234 | Lipkens et al. | Mar 2016 | B2 |
9357293 | Claussen | May 2016 | B2 |
9365815 | Miyazaki et al. | Jun 2016 | B2 |
9368110 | Hershey et al. | Jun 2016 | B1 |
9388363 | Goodson et al. | Jul 2016 | B2 |
9391542 | Wischnewskiy | Jul 2016 | B2 |
9403114 | Kusuura | Aug 2016 | B2 |
9410256 | Dionne et al. | Aug 2016 | B2 |
9416344 | Lipkens | Aug 2016 | B2 |
9421553 | Dionne et al. | Aug 2016 | B2 |
9422328 | Kennedy, III et al. | Aug 2016 | B2 |
9457139 | Ward et al. | Oct 2016 | B2 |
9457302 | Lipkens et al. | Oct 2016 | B2 |
9458450 | Lipkens et al. | Oct 2016 | B2 |
9464303 | Burke | Oct 2016 | B2 |
9476855 | Ward et al. | Oct 2016 | B2 |
9480375 | Marshall et al. | Nov 2016 | B2 |
9480935 | Mariella, Jr. et al. | Nov 2016 | B2 |
9488621 | Kaduchak et al. | Nov 2016 | B2 |
9504780 | Spain et al. | Nov 2016 | B2 |
9512395 | Lipkens et al. | Dec 2016 | B2 |
9513205 | Yu et al. | Dec 2016 | B2 |
9514924 | Morris et al. | Dec 2016 | B2 |
9517474 | Mao et al. | Dec 2016 | B2 |
9567559 | Lipkens | Feb 2017 | B2 |
20020038662 | Schuler et al. | Apr 2002 | A1 |
20020134734 | Campbell et al. | Sep 2002 | A1 |
20030015035 | Kaduchak et al. | Jan 2003 | A1 |
20030028108 | Miller et al. | Feb 2003 | A1 |
20030195496 | Maguire | Oct 2003 | A1 |
20030209500 | Kock et al. | Nov 2003 | A1 |
20030230535 | Affeld et al. | Dec 2003 | A1 |
20040016699 | Bayevsky | Jan 2004 | A1 |
20040035208 | Diaz et al. | Feb 2004 | A1 |
20040112841 | Scott | Jun 2004 | A1 |
20040124155 | Meegan, Jr. | Jul 2004 | A1 |
20040149039 | Cardelius | Aug 2004 | A1 |
20050031499 | Meier | Feb 2005 | A1 |
20050121269 | Namuduri | Jun 2005 | A1 |
20050145567 | Quintel et al. | Jul 2005 | A1 |
20050196725 | Fu | Sep 2005 | A1 |
20060037915 | Strand et al. | Feb 2006 | A1 |
20060037916 | Trampler | Feb 2006 | A1 |
20060050615 | Swisher | Mar 2006 | A1 |
20070053795 | Laugharn, Jr. et al. | Mar 2007 | A1 |
20070224676 | Haq | Sep 2007 | A1 |
20070267351 | Roach et al. | Nov 2007 | A1 |
20070272618 | Gou et al. | Nov 2007 | A1 |
20070284299 | Xu et al. | Dec 2007 | A1 |
20080011693 | Li et al. | Jan 2008 | A1 |
20080067128 | Hoyos et al. | Mar 2008 | A1 |
20080105625 | Rosenberg et al. | May 2008 | A1 |
20080181828 | Kluck | Jul 2008 | A1 |
20080217259 | Siversson | Sep 2008 | A1 |
20080245709 | Kaduchak et al. | Oct 2008 | A1 |
20080245745 | Ward et al. | Oct 2008 | A1 |
20080264716 | Kuiper et al. | Oct 2008 | A1 |
20080272034 | Ferren et al. | Nov 2008 | A1 |
20080272065 | Johnson | Nov 2008 | A1 |
20080316866 | Goodemote et al. | Dec 2008 | A1 |
20090029870 | Ward et al. | Jan 2009 | A1 |
20090045107 | Ward et al. | Feb 2009 | A1 |
20090053686 | Ward et al. | Feb 2009 | A1 |
20090087492 | Johnson et al. | Apr 2009 | A1 |
20090098027 | Tabata et al. | Apr 2009 | A1 |
20090104594 | Webb | Apr 2009 | A1 |
20090126481 | Burris | May 2009 | A1 |
20090178716 | Kaduchak et al. | Jul 2009 | A1 |
20090194420 | Mariella, Jr. et al. | Aug 2009 | A1 |
20090227042 | Gauer et al. | Sep 2009 | A1 |
20090295505 | Mohammadi et al. | Dec 2009 | A1 |
20100000945 | Gavalas | Jan 2010 | A1 |
20100078323 | Takahashi et al. | Apr 2010 | A1 |
20100078384 | Yang | Apr 2010 | A1 |
20100124142 | Laugharn et al. | May 2010 | A1 |
20100139377 | Huang et al. | Jun 2010 | A1 |
20100192693 | Mudge et al. | Aug 2010 | A1 |
20100193407 | Steinberg et al. | Aug 2010 | A1 |
20100206818 | Leong et al. | Aug 2010 | A1 |
20100255573 | Bond et al. | Oct 2010 | A1 |
20100261918 | Chianelli et al. | Oct 2010 | A1 |
20100317088 | Radaelli et al. | Dec 2010 | A1 |
20100323342 | Gonzalez Gomez et al. | Dec 2010 | A1 |
20100330633 | Walther et al. | Dec 2010 | A1 |
20110003350 | Schafran et al. | Jan 2011 | A1 |
20110024335 | Ward et al. | Feb 2011 | A1 |
20110092726 | Clarke | Apr 2011 | A1 |
20110095225 | Eckelberry et al. | Apr 2011 | A1 |
20110123392 | Dionne et al. | May 2011 | A1 |
20110125024 | Mueller et al. | May 2011 | A1 |
20110146678 | Ruecroft et al. | Jun 2011 | A1 |
20110154890 | Holm et al. | Jun 2011 | A1 |
20110166551 | Schafer | Jul 2011 | A1 |
20110189732 | Wienand et al. | Aug 2011 | A1 |
20110245750 | Lynch et al. | Oct 2011 | A1 |
20110262990 | Wang et al. | Oct 2011 | A1 |
20110278218 | Dionne et al. | Nov 2011 | A1 |
20110281319 | Swayze et al. | Nov 2011 | A1 |
20110309020 | Rietman et al. | Dec 2011 | A1 |
20120088295 | Yasuda et al. | Apr 2012 | A1 |
20120145633 | Polizzotti et al. | Jun 2012 | A1 |
20120163126 | Campbell et al. | Jun 2012 | A1 |
20120175012 | Goodwin et al. | Jul 2012 | A1 |
20120231504 | Niazi | Sep 2012 | A1 |
20120267288 | Chen et al. | Oct 2012 | A1 |
20120325727 | Dionne et al. | Dec 2012 | A1 |
20120325747 | Rietman et al. | Dec 2012 | A1 |
20120328477 | Dionne et al. | Dec 2012 | A1 |
20120329122 | Lipkens et al. | Dec 2012 | A1 |
20130017577 | Arunakumari et al. | Jan 2013 | A1 |
20130115664 | Khanna et al. | May 2013 | A1 |
20130175226 | Coussios et al. | Jul 2013 | A1 |
20130217113 | Srinivasan et al. | Aug 2013 | A1 |
20130277316 | Dutra et al. | Oct 2013 | A1 |
20130277317 | LoRicco et al. | Oct 2013 | A1 |
20130284271 | Lipkens et al. | Oct 2013 | A1 |
20140011240 | Lipkens et al. | Jan 2014 | A1 |
20140017758 | Kniep et al. | Jan 2014 | A1 |
20140102947 | Baym et al. | Apr 2014 | A1 |
20140141413 | Laugham, Jr. et al. | May 2014 | A1 |
20140319077 | Lipkens et al. | Oct 2014 | A1 |
20140377834 | Presz, Jr. et al. | Dec 2014 | A1 |
20150053561 | Ward et al. | Feb 2015 | A1 |
20150060581 | Santos et al. | Mar 2015 | A1 |
20150321129 | Lipkens et al. | Nov 2015 | A1 |
20160121331 | Kapur et al. | May 2016 | A1 |
20160123858 | Kapur et al. | May 2016 | A1 |
20160145563 | Berteau et al. | May 2016 | A1 |
20160153249 | Mitri | Jun 2016 | A1 |
20160175198 | Warner et al. | Jun 2016 | A1 |
20160184790 | Sinha et al. | Jun 2016 | A1 |
20160202237 | Zeng et al. | Jul 2016 | A1 |
20160208213 | Doyle et al. | Jul 2016 | A1 |
20160230168 | Kaduchak et al. | Aug 2016 | A1 |
20160237110 | Gilmanshin et al. | Aug 2016 | A1 |
20160237394 | Lipkens et al. | Aug 2016 | A1 |
20160237395 | Lipkens et al. | Aug 2016 | A1 |
20160252445 | Yu et al. | Sep 2016 | A1 |
20160279540 | Presz, Jr. et al. | Sep 2016 | A1 |
20160279551 | Foucault | Sep 2016 | A1 |
20160312168 | Pizzi | Oct 2016 | A1 |
20160314868 | El-Zahab et al. | Oct 2016 | A1 |
20160319270 | Lipkens et al. | Nov 2016 | A1 |
20160325206 | Presz, Jr. et al. | Nov 2016 | A1 |
20160332159 | Dual et al. | Nov 2016 | A1 |
20160339360 | Lipkens et al. | Nov 2016 | A1 |
20160347628 | Dionne et al. | Dec 2016 | A1 |
20160355776 | Lipkens et al. | Dec 2016 | A1 |
20160361670 | Lipkens et al. | Dec 2016 | A1 |
20160363579 | Lipkens et al. | Dec 2016 | A1 |
Number | Date | Country |
---|---|---|
30 27 433 | Feb 1982 | DE |
32 18 488 | Nov 1983 | DE |
196 48 519 | Jun 1998 | DE |
103 19 467 | Jul 2004 | DE |
10 2008 006 501 | Sep 2008 | DE |
0 292 470 | Nov 1988 | EP |
0 641 606 | Mar 1995 | EP |
1 175 931 | Jan 2002 | EP |
1 254 669 | Nov 2002 | EP |
2 420 510 | May 2006 | GB |
9-136090 | May 1997 | JP |
2085933 | Jul 1997 | RU |
629496 | Oct 1978 | SU |
WO 8707178 | Dec 1987 | WO |
WO 8911899 | Dec 1989 | WO |
WO 9005008 | Mar 1990 | WO |
WO 9734643 | Sep 1997 | WO |
WO 9817373 | Apr 1998 | WO |
WO 9850133 | Nov 1998 | WO |
WO 02072234 | Sep 2002 | WO |
WO 03089567 | Oct 2003 | WO |
WO 2004079716 | Sep 2004 | WO |
WO 2009063198 | May 2009 | WO |
WO 2009111276 | Sep 2009 | WO |
WO 2009144709 | Dec 2009 | WO |
WO 2010024753 | Apr 2010 | WO |
WO 2010040394 | Apr 2010 | WO |
WO 2011023949 | Mar 2011 | WO |
WO 2011025890 | Mar 2011 | WO |
WO 2011027146 | Mar 2011 | WO |
WO 2011131947 | Oct 2011 | WO |
WO 2011161463 | Dec 2011 | WO |
WO 2013043297 | Mar 2013 | WO |
WO 2013055517 | Apr 2013 | WO |
WO 2013138797 | Sep 2013 | WO |
WO 2013148376 | Oct 2013 | WO |
WO 2013159014 | Oct 2013 | WO |
WO 2014014941 | Jan 2014 | WO |
WO 2014029505 | Feb 2014 | WO |
WO 2014055219 | Apr 2014 | WO |
WO 2014124306 | Aug 2014 | WO |
WO 2014153651 | Oct 2014 | WO |
WO 2015006730 | Jan 2015 | WO |
Entry |
---|
Alvarez et al.; Shock Waves, vol. 17, No. 6, pp. 441-447, 2008. |
Benes et al.; Ultrasonic Separation of Suspended Particles, 2001 IEEE Ultrasonics Symposium; Oct. 7-10, 2001; pp. 649-659; Atlanta, Georgia. |
Castilho et al.; Animal Cell Technology: From Biopharmaceuticals to Gene Therapy; 11—Animal Cell Separation; 2008. |
Castro; Tunable gap and quantum quench dynamics in bilayer graphene; Jul. 13, 2010; Mathematica Summer School. |
Cravotto et al.; Ultrasonics Sonochemistry, vol. 15, No. 5, pp. 898-902, 2008. |
Garcia-Lopez, et al; Enhanced Acoustic Separation of Oil-Water Emulsion in Resonant Cavities. The Open Acoustics Journal. 2008, vol. 1, pp. 66-71. |
Hill et al.; Ultrasonic Particle Manipulation; Microfluidic Technologies for Miniaturized Analysis Systems, Jan. 2007, pp. 359-378. |
Ilinskii et al.; Acoustic Radiation Force on a Sphere in Tissue; AIP Conference Proceedings; 2012. |
Kuznetsova et al.; Microparticle concentration in short path length ultrasonic resonators: Roles of radiation pressure and acoustic streaming; Journal of the Acoustical Society of America, American Institute of Physics for the Acoustical Society of America, vol. 116, No. 4, Oct. 1, 2004, pp. 1956-1966, DOI: 1.1121/1.1785831. |
Latt et al.; Ultrasound-membrane hybrid processes for enhancement of filtration properties; Ultrasonics sonochemistry 13.4 (2006): 321-328. |
Li et al.; Electromechanical behavior of PZT-brass unimorphs; J. Am. Ceram. Soc. vol. 82; No. 7; pp. 1733-1740, 1999. |
Lipkens et al.; Frequency sweeping and fluid flow effects on particle trajectories in ultrasonic standing waves; Acoustics 08, Paris, Jun. 29-Jul. 4, 2008. |
Lipkens et al.; Prediction and measurement of particle velocities in ultrasonic standing waves; J. Acoust. Soc. Am., 124 No. 4, pp. 2492 (A) 2008. |
Lipkens et al.; Separation of micron-sized particles in macro-scale cavities by ultrasonic standing waves; Presented at the International Congress on Ultrasonics, Santiago; Jan. 11-17, 2009. |
Lipkens et al.; The effect of frequency sweeping and fluid flow on particle trajectories in ultrasonic standing waves; IEEE Sensors Journal, vol. 8, No. 6, pp. 667-677, 2008. |
Lipkens et al.; Separation of bacterial spores from flowering water in macro-scale cavities by ultrasonic standing waves; submitted/uploaded to http://arxiv.org/abs/1006.5467 on Jun. 28, 2010. |
Lipkens et al., Macro-scale acoustophoretic separation of lipid particles from red blood cells, The Journal of the Acoustical Society of America, vol. 133, Jun. 2, 2013, p. 045017, XP055162509, New York, NY. |
Meribout et a.; An Industrial-Prototype Acoustic Array for Real-Time Emulsion Layer Detection in Oil Storage Tanks; IEEE Sensors Journal, vol. 9, No. 12, Dec. 2009. |
Nilsson et al.; Review of cell and particle trapping in microfluidic systems; Department of Measurement Technology and Industrial Electrical Engineering, Div. of Nanobiotechnology, Lund University, P.O. Box 118. Lund, Sweden, Analytica Chimica Acta 649, Jul. 14, 2009, pp. 141-157. |
Pangu et al.; Droplet transport and coalescence kinetics in emulsions subjected to acoustic fields; Ultrasonics 46, pp. 289-302 (2007). |
Ponomarenko et al.; Density of states and zero Landau level probed through capacitance of graphene; Nature Nanotechnology Letters, Jul. 5, 2009; DOI: 10.1038/NNANO.2009.177. |
Ryll et al.; Performance of Small-Scale CHO Perfusion Cultures Using an Acoustic Cell Filtration Device for Cell Retention: Characterization of Separation Efficiency and Impact of Perfusion on Product Quality; Biotechnology and Bioengineering; vol. 69; Iss. 4; pp. 440-449; Aug. 2000. |
Seymour et al, J. Chem. Edu., 1990, 67(9), p. 763, published Sep. 1990. |
Volpin et al.; Mesh simplification with smooth surface reconstruction; Computer-Aided Design; vol. 30; No. 11; 1998. |
Wang et al.; Retention and Viability Characteristics of Mammalian Cells in an Acoustically Driven Polymer Mesh; Biotechnol. Prog. 2004, pp. 384-387 (2004). |
Wicklund et al.; Ultrasonic Manipulation of Single Cells; Methods in Molecular Biology; vol. 853; pp. 1777-196; 2012. |
Annex to Form PCT/ISA/206—Communication Relating to the Results of the Partial International Search Report, dated Jul. 18, 2013. |
European Search Report of European Application No. 11769474.5, dated Sep. 5, 2013. |
European Search Report of European Application No. 13760840.2, dated Feb. 4, 2016. |
European Search Report of European Application No. 13721179.3 dated Feb. 23, 2016. |
International Search Report and Written Opinion dated Dec. 20, 2011, for corresponding PCT application No. PCT/US2011/032181. |
International Search Report and Written Opinion dated Feb. 27, 2012, for PCT application No. PCT/US2011/040787. |
International Search Report and Written Opinion of International Application No. PCT/US2012/051804 dated Nov. 16, 2012. |
International Search Report and Written Opinion of International Application No. PCT/US2013/037404 Dated Jun. 21, 2013. |
International Search Report and Written Opinion of International Application No. PCT/US2013/032705 dated Jul. 26, 2013. |
International Search Report and Written Opinion of International Application No. PCT/US2013/050729 Dated Sep. 25, 2013. |
International Search Report dated Feb. 18, 2014 in corresponding PCT Application No. PCT/US2013/059640. |
International Search Report for corresponding PCT Application Serial No. PCT/US2014/015382 dated May 6, 2014. |
International Search Report for PCT/US2014/035557 dated Aug. 27, 2014. |
International Search Report for PCT/US2014/043930 dated Oct. 22, 2014. |
International Search Report for PCT/US2014/046412 dated Oct. 27, 2014. |
International Search Report for PCT/US2014/064088 dated Jan. 30, 2015. |
Extended European Search Report for Application No. EP 12833859.7 dated Mar. 20, 2015. |
International Search Report and Written Opinion for International Application No. PCT/US2015/010595 dated Apr. 15, 2015. |
International Search Report for PCT/US2015/019755 dated May 4, 2015. |
International Search Report mailed Jul. 30, 2015 for International Application No. PCT/US2015/030009. |
International Search Report for PCT/US2015/039125 dated Sep. 30, 2015. |
International Search Report and Written Opinion for PCT Application Serial No. PCT/US2015/053200 dated Dec. 28, 2015. |
European Search Report of European Application No. 11796470.0 dated Jan. 5, 2016. |
International Search Report and Written Opinion for International Application No. PCT/US2015/066884, dated Mar. 22, 2016. |
International Search Report and Written Opinion for International Application No. PCT/US2016/024082 dated Jun. 27, 2016. |
International Search Report and Written Opinion for International Application No. PCT/US2016/044586 dated Oct. 21, 2016. |
International Search Report and Written Opinion for International Application No. PCT/US2016/031357 dated Jul. 26, 2016. |
International Search Report and Written Opinion for International Application No. PCT/US2015/024365 dated Oct. 13, 2016. |
International Search Report and Written Opinion for International Application No. PCT/US2016/041664 dated Oct. 18, 2016. |
International Search Report and Written Opinion for International Application No. PCT/US2016/049088 dated Nov. 28, 2016. |
International Search Report and Written Opinion for International Application No. PCT/US2016/050415 dated Nov. 28, 2016. |
International Search Report and Written Opinion for International Application No. PCT/US2016/037104 dated Dec. 16, 2016. |
Phys. Org. “Engineers develop revolutionary nanotech water desalination membrane.” Nov. 6, 2006. http://phys.org/news82047372.html. |
“Proceedings of the Acoustics 2012 Nantes Conference,” Apr. 23-27, 2012, Nantes, France, pp. 278-282. |
Sony New Release: <http://www.sony.net/SonyInfo/News/Press/201010/10-137E/index.html>. |
Number | Date | Country | |
---|---|---|---|
20170159007 A1 | Jun 2017 | US |
Number | Date | Country | |
---|---|---|---|
61761717 | Feb 2013 | US | |
61611159 | Mar 2012 | US | |
61611240 | Mar 2012 | US | |
61708641 | Oct 2012 | US | |
61754792 | Jan 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15238624 | Aug 2016 | US |
Child | 15432888 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14175766 | Feb 2014 | US |
Child | 15238624 | US | |
Parent | 14026413 | Sep 2013 | US |
Child | 14175766 | US | |
Parent | 13844754 | Mar 2013 | US |
Child | 14026413 | US |